Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Leap Therapeutics Inc (LPTX)

Leap Therapeutics Inc (LPTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,755
  • Shares Outstanding, K 41,440
  • Annual Sales, $ 0 K
  • Annual Income, $ -67,560 K
  • EBIT $ -71 M
  • EBITDA $ -71 M
  • 60-Month Beta -0.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.82
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.70
  • Most Recent Earnings $-0.37 on 05/13/25
  • Next Earnings Date 05/12/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 167.49% ( +13.46%)
  • Historical Volatility 93.37%
  • IV Percentile 46%
  • IV Rank 16.36%
  • IV High 939.02% on 04/17/25
  • IV Low 16.56% on 06/13/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 31
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 3,780
  • Open Int (30-Day) 3,799

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.29
  • Number of Estimates 1
  • High Estimate -0.29
  • Low Estimate -0.29
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +44.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3200 +12.94%
on 05/20/25
0.4300 -15.95%
on 05/01/25
+0.0018 (+0.50%)
since 04/21/25
3-Month
0.2223 +62.57%
on 04/04/25
0.6500 -44.40%
on 03/26/25
-0.1188 (-24.74%)
since 02/21/25
52-Week
0.2223 +62.57%
on 04/04/25
4.7900 -92.46%
on 10/30/24
-2.1486 (-85.60%)
since 05/21/24

Most Recent Stories

More News
Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe

KURA : 6.20 (-2.82%)
SHPH : 0.1861 (-7.23%)
LPTX : 0.3614 (-4.94%)
NXTC : 0.5064 (-0.39%)
ACET : 0.7000 (-6.59%)
Leap Therapeutics Stock Plunges To Record Low After Ending Gastric Cancer Drug Trials, Retail Bets On CRC Pipeline

While sirexatamab combined with tislelizumab and chemotherapy showed some activity in biomarker-specific populations, the study failed to generate a clear positive signal on progression-free survival endpoints....

PINK : 28.20 (-2.55%)
IWC : 117.51 (-2.82%)
VXF : 181.00 (-2.65%)
LPTX : 0.3614 (-4.94%)
Leap Therapeutics Reports Second Quarter 2023 Financial Results

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

LPTX : 0.3614 (-4.94%)
Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

LPTX : 0.3614 (-4.94%)
Leap Therapeutics Announces Reverse Stock Split

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

LPTX : 0.3614 (-4.94%)
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today...

LPTX : 0.3614 (-4.94%)
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today...

LPTX : 0.3614 (-4.94%)
Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

LPTX : 0.3614 (-4.94%)
Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

LPTX : 0.3614 (-4.94%)
Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

LPTX : 0.3614 (-4.94%)

Business Summary

Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States.

See More

Key Turning Points

3rd Resistance Point 0.5181
2nd Resistance Point 0.4665
1st Resistance Point 0.4233
Last Price 0.3614
1st Support Level 0.3285
2nd Support Level 0.2769
3rd Support Level 0.2337

See More

52-Week High 4.7900
Fibonacci 61.8% 3.0451
Fibonacci 50% 2.5062
Fibonacci 38.2% 1.9672
Last Price 0.3614
52-Week Low 0.2223

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar